Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study

AIM: The glucagon-like peptide-1 receptor agonists exenatide once weekly (QW) and liraglutide once daily (QD) have demonstrated improvements in glycemic outcomes in patients with type 2 diabetes mellitus in randomized clinical trials. However, little is known about their real-world comparative effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Saunders, William B, Nguyen, Hiep, Kalsekar, Iftekhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956055/
https://www.ncbi.nlm.nih.gov/pubmed/27486339
http://dx.doi.org/10.2147/DMSO.S103972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956055/
https://www.ncbi.nlm.nih.gov/pubmed/27486339
http://dx.doi.org/10.2147/DMSO.S103972

Ejemplares similares